Dr. Douglas Blayney from Stanford University to Join to Discuss Recently Announced Clinical Data
NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report second-quarter 2018 financial results and host an operational and clinical update conference call on Tuesday, October 23, 2018, at 8:00 a.m. Eastern Time. BeyondSpring’s management team will be joined by Dr. Douglas Blayney, global Principal Investigator for BeyondSpring’s chemotherapy-induced neutropenia (CIN) development program and Professor of Medicine at Stanford University Medical Center, to highlight recently announced clinical data.
The conference call may be accessed by dialing (866) 362-6591 (U.S.) or (706) 758-3199 (international) and referencing conference ID 7880008. A live webcast will be available on the Investors page of the Company's website at http://ir.beyondspringpharma.com. An archived replay of the webcast will be available for 30 days.
BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using a ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has a seasoned management team with many years of experience bringing drugs to the global market.
Caitlin Kasunich / Amrita Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
firstname.lastname@example.org / email@example.com
Laura Perry / Joe Rayne